Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Pharsight Q4 and Year-over-Year Revenue Up

SAN FRANCISCO, April 30 - Pharsight today reported increased quarterly and year-over-year revenue.


Total revenue for the fiscal year ended March 31, 2002increased to $14.2 million compared to $11.9 million for the previous year.


Total revenue for the quarter ended March 31 were $3.8 million compared with $3 million in the year-ago period. The net loss for the quarter dropped to $3.4 million, or $.18 per share, from $6 million, or $.33 a share, for the same period a year ago.

R&D for the fiscal year dropped to $6.6 million from $8.1 million in the previous year. R&D spending was cut back to $1.5 million in the fourth quarter from $2.3 million for the year-ago period. 


Pharsight revised its projection of EBITDA breakeven for the end of June 2003 from previously announced end of calendar year 2002.


The company said it had $13.6 million in cash, cash equivalents, and short-term investments as of March 31.


For more information, click here.


Pharsight also said today that it signed Aventis Pharma to a software and support deal, its largest customer deal to date, according to the company.


The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.